Sort

Search

01/01/2023 Telemedicine in Neuromuscular Diseases During Covid-19 Pandemic: ERN-NMD European Survey
El-Hassar L., Amara A., Sanson B., Lacatus O., Belhouchet, AA, Kroneman M., Claeys K., Plancon, JP, Rodolico C., Primiano G., Trojsi F., Filosto M., Mongini T.E., Bortolani S., Monforte M., Carraro E., Maggi L., Ricci F., Silani V., Orsucci D., Créange A., Péréon Y., Stojkovic T., van der Beek, NAME, Toscano A., Pareyson D., Attarian S., Van den Bergh, PYK, Remiche G., Hoeijmakers, JGJ, Badrising U., Voermans N.C., Kaindl A.M., Schara-Schmidt U., Schoser B., Gazzerro E., Haberlová J., Vohanka, S, Pál E., Molnar M.J., Leonardis L., Tournev I.L., Osorio A.N., Olivé M., Muelas N., Alonso-Perez J., Plá F., De Visser M., Siciliano G., Sacconi S.. Telemedicine in Neuromuscular Diseases During Covid-19 Pandemic: ERN-NMD European Survey. Journal Of Neuromuscular Diseases. 2023; 10(2)DOI:10.3233/JND-221525. PMID:36373291. IF:3.200(Q2/3D).
01/01/2023 mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis
Blanco Y., Escudero D., Lleixà C., Llufriu S., Egri N., García R.R., Alba M., Aguilar E., Artola M., Aldea Novo M., Alvarez S., Caballero E., Cabrera-Maqueda J.M., Fonseca E., Guasp M., Hernando A., Martinez-Hernandez E., Olivé-Cirera G., Lopez-Contreras J., Martín-Aguilar L., Martinez-Martinez L., Rombauts A., Rodés M., Sabater L., Sepulveda M., Solana E., Tejada-Illa C., Vidal-Fernández N., Vilella A., Fortuny C., Armangué T., Dalmau J.O., Querol L., Saiz A.. mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis. Neurology-Neuroimmunology & Neuroinflammation. 2023; 10(6)DOI:10.1212/NXI.0000000000200163. PMID:37679040. IF:(Q/D).
01/01/2023 CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome
Al-Hakem H., Doets A.Y., Stino A.M., Zivkovic S.A., Andersen H., Willison H.J., Cornblath D.R., Gorson K.C., Islam Z., Mohammad Q.D., Sindrup Sø.H., Kusunoki S., Davidson A., Casasnovas C., Bateman K., Miller J.A.L., Van Den Berg B., Verboon C., Roodbol J., Leonhard S.E., Arends S., Luijten L.W.G., Benedetti L., Kuwabara S., Van Den Bergh P., Monges S., Marfia G.A., Shahrizaila N., Galassi G., Pereon Y., Burmann J., Kuitwaard K., Kleyweg R.P., Marchesoni C., Tous M.J.S., Querol L., Martin-Aguilar L., Wang Y., Nobile-Orazio E., Rinaldi S., Schenone A., Pardo J., Vermeij F.H., Waheed W., Lehmann H.C., Granit V., Stein B., Cavaletti G., Gutierrez-Gutierrez G., Barroso F.A., Visser L.H., Katzberg H.D., Dardiotis E., Attarian S., Van Der Kooi A.J., Eftimov F., Wirtz P.W., Samijn J.P.A., Jacobus Gilhuis H., Hadden R.D.M., Holt J.K.L., Sheikh K.A., Kolb N., Karafiath S., Vytopil M., Antonini G., Feasby T.E., Faber C., Kramers H., Busby M., Roberts R.C., Silvestri N.J., Fazio R., Van Dijk G.W., Garssen M.P.J., Verschuuren J., Harbo T., Jacobs B.C.. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome. NEUROLOGY. 2023; 100(23)DOI:10.1212/WNL.0000000000207282. PMID:37076309. IF:8.400(Q1/1D).
01/01/2023 Rituximab treatment in myasthenia gravis
Vesperinas-Castro A., Cortés-Vicente E.. Rituximab treatment in myasthenia gravis. Frontiers in Neurology. 2023; 14DOI:10.3389/fneur.2023.1275533. PMID:37849836. IF:2.700(Q2/4D).
01/01/2023 Colorimetric fusion of attenuation and birefringence in OCT signatures: a screening tool for evaluating muscular degradation in alpha-sarcoglican deficit murine models
Mieites V., Pardo A., Gutiérrez-Gutiérrez J.A., Suárez-Calvet X., López-Higuera J.M., Díaz-Manera J., Conde O.M.. Colorimetric fusion of attenuation and birefringence in OCT signatures: a screening tool for evaluating muscular degradation in alpha-sarcoglican deficit murine models. Proceedings of SPIE. 2023; 12632DOI:10.1117/12.2670555. PMID:. IF:(Q/D).
01/01/2023 Wide-field optical properties estimation of whole limbs in muscle dystrophy murine models via SFDI: A case study
Mieites V., Gutíerrez-Gutíerrez J.A., Pardo A., Súarez-Calvet X., Lopez-Higuera J.M., Diaz-Manera J., Conde O.M.. Wide-field optical properties estimation of whole limbs in muscle dystrophy murine models via SFDI: A case study. Proceedings of SPIE. 2023; 12627DOI:10.1117/12.2670573. PMID:. IF:(Q/D).
01/01/2023 Falls Predict Acute Hospitalization in Parkinson's Disease.
Santos García D, de Deus Fonticoba T, Cores C, Castro ES, Hernández Vara J, Jesús S, Mir P, Cosgaya M, Martí MJ, Pastor P, Cabo I, Seijo M, Legarda I, Vives B, Caballol N, Rúiz Martínez J, Croitoru I, Cubo E, Miranda J, Alonso Losada MG, Labandeira C, López Ariztegui N, Morales-Casado M, González Aramburu I, Infante J, Escalante S, Bernardo N, Blázquez Estrada M, Menéndez González M, Caldentey JG, Borrué C, Vela L, Catalán MJ, Gómez Mayordomo V, Kurtis M, Prieto C, Ordás C, Nogueira V, López Manzanares L, Ávila Rivera MA, Puente V, García Moreno JM, Solano Vila B, Álvarez Sauco M, Carrillo Padilla F, Carlos Martínez Castrillo J, Sánchez Alonso P, Gastón I, Kulisevsky J, Valero C, de Fábregues O, González Ardura J, López Díaz LM, Martinez-Martin P. Falls Predict Acute Hospitalization in Parkinson's Disease.. Journal of Parkinsons Disease. 2023; 13(1)DOI:10.3233/JPD-212539. PMID:33843696. IF:4.000(Q2/3D).
01/01/2023 Non-Persistence of Tremorolytic Effect of Perampanel in Essential Tremor: Real-World Experience with 50 Patients
Gironell A., Pascual-Sedano B., Marín-Lahoz J., Pérez J., Pagonabarraga J.. Non-Persistence of Tremorolytic Effect of Perampanel in Essential Tremor: Real-World Experience with 50 Patients. Movement Disorders Clinical Practice. 2023; 10(1)DOI:10.1002/mdc3.13576. PMID:36704076. IF:2.600(Q2/5D).